-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang No.4 Pharmaceutical: Pressing the “Fast-Forward” Button on Production and Sales
Category:
Time：2020-03-23
We remain vigilant in our epidemic prevention and control efforts, so why should we fear the arrival of cold snaps with the onset of spring? In recent days, our province has been coordinating epidemic prevention and control with economic and social development. All localities and departments have seized every moment to diligently cultivate the land and accelerate production, ensuring that the Yanzhao region’s resumption of work and production has already stepped into spring.
We remain steadfast in our epidemic prevention and control efforts, so why should we fear the arrival of cold snaps with the onset of spring? In recent days, our province has been coordinating epidemic prevention and control with economic and social development. All localities and departments have seized the springtime opportunity to work diligently, racing against time to ramp up production. Across the Yanzhao region, resumption of work and production has already entered the spring season.
After the outbreak of the epidemic, pharmaceutical companies across the province swiftly ramped up production. Companies such as Huayao, Shiyao, Yiling Pharmaceutical, and Shenwei Pharmaceutical all put aside their holiday breaks, ensuring a steady and abundant supply of medicines to the front lines of epidemic prevention and control.
Among them, Shijiazhuang No.4 Pharmaceutical Co., Ltd. promptly adjusted its production schedule, keeping its equipment running around the clock to expand capacity and increase inventory. Given the current global pandemic situation, Shijiazhuang No.4 Pharmaceutical is not only ensuring a steady supply of both emergency and routine medications but also maintaining strong export sales. Now, let’s connect with our reporter who is currently at Shijiazhuang No.4 Pharmaceutical for more details.
Reporter
I’m currently in the infusion production workshop of Shijiazhuang No.4 Pharmaceutical Co., Ltd. Although it’s already late in the evening, the workshop is brightly lit. In the production workshop where I’m standing, over a hundred employees are busily and efficiently at work. Right beside me, boxes of PP plastic-bottle infusion products are continuously coming off the assembly line and being stored in the warehouse.
We’ve just learned that these products will soon be exported to countries in Africa and Southeast Asia. Next, we’re pleased to welcome Li Bo, Manager of the Foreign Trade Department at Shijiazhuang Sihua Pharmaceutical Co., Ltd., who will share with us the company’s current production status.
Li Bo
Currently, Shijiazhuang Sihua Pharmaceutical Co., Ltd. has fully resumed production and operations. In addition to continuing to ensure the production of emergency medicines for the epidemic, all other production lines have been operating at full capacity in two shifts. The company’s flagship product—large-volume intravenous solutions—is now being shipped from the warehouse at a daily rate exceeding 4.5 million bottles, returning to normal levels.
Reporter
So, what about the foreign trade export situation?
Li Bo
The company adheres to a dual-channel sales strategy. Currently, our foreign trade sales staff primarily communicate with and negotiate business deals with overseas customers via telephone, email, and other similar channels. In the first two months of this year, the company’s foreign trade sales continued to maintain double-digit growth.
Reporter
We’ve just learned that many of the epidemic-prevention drugs produced by Shisi Pharmaceutical have played a highly effective and positive role in the current fight against the pandemic. So, have you considered introducing these drugs into the international market?
Li Bo
Currently, while continuing to focus on our regular export products, we are placing particular emphasis on strengthening the international marketing efforts for certain antiviral and antibacterial drugs that have been widely used during the pandemic—such as Abidol capsules, moxifloxacin hydrochloride sodium chloride injection, and our company’s disinfectant products. At present, we are working closely with our overseas customers to carry out preliminary market-access activities tailored to their specific needs.
Reporter
We also believe that, through the joint efforts of large enterprises like Shiyao Group, critical anti-epidemic medications can continue to meet the demands of both domestic and international markets, thereby providing a solid guarantee for overcoming the pandemic.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license